GlassScriptPhysician profile
Sara Altaf Awan
NPI 1235748799
$761.11
in general payments reported to CMS, 2019-2025
18 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.62 · 2022: $48.96 · 2024: $122 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $106.36 | 2024-2025 | |
| Abbvie INC. | $89.74 | 2025 | |
| Novo Nordisk INC | $73.72 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $66.28 | 2022-2025 | Strensiq |
| Lilly USA, LLC | $62.48 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $53.42 | 2025 | Airsupra, Tezspire |
| Corcept Therapeutics | $49.46 | 2024-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $40.31 | 2024-2025 | Voquezna |
| Dexcom, INC. | $35.04 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.61 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $31.26 | 2025 | Repatha, Otezla |
| Madrigal Pharmaceuticals | $24.41 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $21.76 | 2025 | |
| Spr Therapeutics, INC | $19.25 | 2025 | Sprint Pns System |
| Novartis Pharmaceuticals Corporation | $18.23 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.25 | 2025 | Gvoke Hypopen |
| Capsovision, INC. | $15.37 | 2024 | Capsocam Plus |
| Dynavax Technologies Corporation | $5.16 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.